COMP <GO>
AGEN vs EIKN // EV/EBITDA & P/E VALUATION
Agenus Inc. (NASDAQ) VS. Eikon Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AGEN 2
— EIKN 0
■ METRIC PARITY
LAST: $7.09 (-0.56%) • MKT CAP: $320.2M
valuation
—
LAST: $5.35 (-3.43%) • MKT CAP: $289.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGEN VS. EIKN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGEN | EIKN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.11% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -17.70% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -2.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 28.2 | +18.53 | AGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $320.2M | $289.8M | $30.4M | AGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGEN REV | EIKN REV | AGEN GROSS % | EIKN GROSS % | AGEN FCF | EIKN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $114.2M | $0 | 98.0% | — | -$77.2M | — |
| FY 2024 | $103.5M | — | 98.0% | — | -$158.9M | — |
| FY 2023 | $156.3M | — | — | — | -$224.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGEN // BETA —
EIKN // BETA —